Multiply Labs develops advanced, cloud-controlled robotic systems to automate small-batch and individualized pharmaceutical manufacturing. The company provides robotic manufacturing capacity-as-a-service, focusing on personalized capsules for clinical trials and robotic production of cell therapies. Its platform leverages collaborative robots, cloud-controlled fleets, and digital quality control to scale the production of individualized drugs. Multiply Labs is developing experimental cell-therapy production systems in collaboration with a consortium of industrial and research organizations. The company plans to grow its installed production capacity and expand its range of applications to new therapies. Financially, the business has raised more than $25 million to date, including a newly announced Series A. Multiply Labs has developed a 3D printing technology that prints customized pills for nutraceutical use. Its platform produces single pills whose supplement and active-principle content is personalized to patients' unique metabolic needs. The company was co-founded by a team of MIT and University of Milan researchers, including Federico Parietti (CEO) and Alice Melocchi (CTO), and was accelerated within Y Combinator. Multiply Labs plans to use new capital to build an advanced production facility where client orders will be received and realized on demand via a dosage robotic system. Financially, the company raised $2.7M in venture capital and had previously raised about $120K from Y Combinator and its partners.

Total raised

$23M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2021